Emiltatug Ledadotin (Emi-Le, XMT-1660)
Sources
company_release, as of 2026-11-07
Servier release, 06.01.2026 (company release; opened 2026-10-27), ASCO 2026 oral abstract 6010 (doi 10.1200/JCO.2026.44.16_suppl.6010; abstract not opened): Emi-Le (B7-H4 ADC) Phase 1; 45 evaluable ACC patients ORR 35.6% (one CR), DCR 82.2%; post hoc aggressive subtype n 32 ORR 46.9%, DCR 81.3%, median PFS 7.8 months; TRAEs leading to discontinuation 3.9% (all patients); grade 3 AST increase 20% and proteinuria 23%; no grade 4 or 5 TRAEs. FDA Breakthrough Therapy designation (ACC with solid histology or high-grade transformation). Preliminary.
Brief source A15
company_release, as of 2026-11-07
Servier release, 10.19.2026 (company release; opened 2026-10-27): first patients dosed in the pivotal Phase 2 EMBLEM-1 cohort (NCT05377996); primary endpoint ORR per RECIST 1.1 (confirmed CR or PR); Breakthrough Therapy designation; no FDA-approved systemic option; ACC diagnosed in about four per million people per year (company figure). No filing date disclosed.
Brief source A16
publication, as of 2026-11-07
OncLive, 06.16.2026 (trade press on the ASCO 2026 oral presentation; opened 2026-10-27): Emi-Le 95% CI for ORR 46.9% is 29.1% to 65.3%; DoR 6.4 months (aggressive subtype) and 7.4 months (n 45); ACC cohort n 48: any grade TRAEs 100%, grade 3 TRAEs 79.2% (51.1% in all 180), TRAE discontinuation 2.1% (1 patient), dose reduction 45.8%, dose delay 56.3%; proteinuria the leading cause of dose changes, proteinuria-related dose reductions fell from 38.9% to 20% after a monitoring amendment; EMBLEM-1 dose 80 mg/m2 every 4 weeks, cap 160 mg; Breakthrough designation May 2026; historical median PFS of 2 to 3 months in aggressive ACC-I (presenter, citing prior trials); about 30% to 40% of patients have the aggressive phenotype.
Brief source A17
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT05377996
A Phase 1/2, First-in-human, Multicenter Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
ClinicalTrials.gov API v2 record, retrieved 2026-11-07